Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)
Chung-Feng Huang,Kuo-Chih Tseng,Pin-Nan Cheng,Chao-Hung Hung,Ching-Chu Lo,Cheng-Yuan Peng,Ming-Jong Bair,Ming-Lun Yeh,Chien-Hung Chen,Pei-Lun Lee,Chun-Yen Lin,Hsing-Tao Kuo,Chun-Ting Chen,Chi-Chieh Yang,Jee-Fu Huang,Chi-Ming Tai,Jui-Ting Hu,Chih-Lang Lin,Wei-Wen Su,Wei-Lun Tsai,Yi-Hsiang Huang,Chien-Yu Cheng,Chih-Lin Lin,Chia-Chi Wang,Sheng-Shun Yang,Lein-Ray Mo,Guei-Ying Chen,Chun-Chao Chang,Szu-Jen Wang,Chia-Sheng Huang,Tsai-Yuan Hsieh,Chih-Wen Lin,Tzong-Hsi Lee,Lee-Won Chong,Chien-Wei Huang,Shiuh-Nan Chang,Ming-Chang Tsai,Shih-Jer Hsu,Jia-Horng Kao,Chun-Jen Liu,Chen-Hua Liu,Han-Chieh Lin,Mei-Hsuan Lee,Pei-Chien Tsai,Chia-Yen Dai,Wan-Long Chuang,Chi-Yi Chen,Ming-Lung Yu
DOI: https://doi.org/10.1016/j.cgh.2021.07.037
IF: 13.576
2022-05-01
Clinical Gastroenterology and Hepatology
Abstract:Background & AimsSofosbuvir is approved for chronic hepatitis C (CHC) patients with severe chronic kidney disease (CKD). The impact of sofosbuvir-based therapy on renal function augmentation on a real-world nationwide basis is elusive.MethodsThe 12,995 CHC patients treated with sofosbuvir-based (n = 6802) or non–sofosbuvir-based (n = 6193) regimens were retrieved from the Taiwan nationwide real-world HCV Registry Program. Serial estimated glomerular filtration rate (eGFR) levels were measured at baseline, end of treatment (EOT), and end of follow-up (EOF) (3 months after EOT).ResultsThe eGFR decreased from baseline (91.4 mL/min/1.73 m2) to EOT (88.4 mL/min/1.73 m2; P < .001) and substantially recovered at EOF (88.8 mL/min/1.73 m2) but did not return to pretreatment levels (P < .001). Notably, a significant decrease in eGFR was observed only in patients with baseline eGFR ≥90 mL/min/1.73 m2 (from 112.9 to 106.4 mL/min/1.73 m2; P < .001). In contrast, eGFR increased progressively in patients whose baseline eGFR was <90 mL/min/1.73 m2 (from 70.0 to 71.5 mL/min/1.73 m2; P < .001), and this increase was generalized across different stages of CKD. The trend of eGFR amelioration was consistent irrespective of sofosbuvir usage. Multivariate adjusted analysis demonstrated that baseline eGFR >90 mL/min/1.73 m2 was the only factor independently associated with significant slope coefficient differences of eGFR (–1.98 mL/min/1.73 m2; 95% confidence interval, –2.24 to –1.72; P < .001). The use of sofosbuvir was not an independent factor associated with eGFR change.ConclusionsBoth sofosbuvir and non–sofosbuvir-based regimens restored renal function in CHC patients with CKD, especially in those with significant renal function impairment.
gastroenterology & hepatology